Over the last decade the CBD market has made some huge strides forward, but, in 2019, the market has exploded.
From 2015 to 2018, Cannabidiol (CBD) product sales in the US grew an estimated 300% from $200 million to $620 million. This year, CBD sales in the US are estimated to reach a whopping $5 billion, according to a recent Brightfield Group industry analysis report.
Compared to the $200 million of sales in 2015, that’s over 2500% growth!
While the growth of the CBD market in 2019 is beyond ridiculous, experts believe that CBD sales will continue to skyrocket and reach $25 billion by 2025.
With 2020 just around the corner, here’s what we expect will happen in the CBD industry during this upcoming year.
Cannabis Legalization in 2020
Last year, hemp-derived CBD was federally legalized under the 2018 Agricultural Improvement Act; however, unclear laws have kept CBD intertwined with the legal complications of Cannabis in some states. Because of this, it’s important to also stay up to date on cannabis legalization laws overall.
From 1996 to the present day, 33 states have legalized cannabis for medical use, and 11 of those states have legalized cannabis for recreational adult use. In the remaining 17 states, cannabis remains fully illegal in 11 states and decriminalized in 3 of those 11 states. In the remaining states, the legal status is mixed or unclear
2020 will be a major voting year, and as the end of 2019 draws near, 6 states are actively pushing to get recreational cannabis legalization initiatives onto the ballot.
New York: No longer under the heat as the first legislature to tax and regulate cannabis, NY may likely feel more comfortable about voting, yes and the struggle to achieve cannabis legalization in New York will finally end.
New Mexico: On January 21, a legislative session to legalize recreational cannabis use will begin and last just 30-days. With substantial support from Gov. Grisham, New Mexico is positioned to legalize recreational cannabis use; however, many are hesitant to get their hopes up since a similar legislative session in 2019 died in the Senate after passing the House.
New Jersey: Last Monday, on December 16, the New Jersey Marijuana Legalization Amendment reached the number of required signatures and was passed and placed on the ballot. With over 62% of New Jersey residents in support of legalization, according to a recent survey from Monmouth University, combined with the major tax incentives gained by legalization, Recreational Cannabis legalization in the Garden State is a high possibility.
Arizona: Arizona is on track to reach the 237,645 required signatures by the July 2, 2020 deadline and will likely appear on the November 2020 ballot. As the second attempt at legalization, following a narrow disapproval in 2016, and with clear tax incentives, legalizing recreational cannabis is the logical choice for Arizona with a high chance of getting passed.
Arkansas: Arkansas is on track to reach the 89,151 required signatures and will likely appear on the November 2020 ballot; however as a Republican-dominant state, the Arkansas Marijuana Legalization Initiative may not get the support it needs.
Florida: It is highly unlikely that the Florida Marijuana Legalization Initiative will reach the 766,200 required signatures by February 2020 and will likely not appear on the 2020 ballot
Missouri: While Missouri may still appear on the ballot if the legalization initiative reaches 160,199 signatures by May 3, 2020, Missouri voters’ support for legalization is very unclear.
South Dakota: South Dakota did not receive enough signatures to get put on the ballot in 2020.
Ohio: Ohio did not receive enough signatures to get put on the ballot in 2020.
Idaho: Idaho is on track to reach required 55,057 signatures by May 2020 and will likely get put on the ballot by November 2020.
Consumers Will Demand for Higher Lab Testing Standards and Increased Transparency from Companies
Due to a lack of consumer awareness and CBD regulations, there has been little pressure on brands to properly and thoroughly test their products. As a result, many brands will only test one out of every thousand or more units for just cannabinoid potency. This is the bare minimum of cannabis testing that will not detect a majority of the harmful compounds that can be found in cannabis-derived products and will not ensure the product is safe or pure.
As consumers become more informed about CBD, they are becoming more aware of the importance and scope of lab testing. Soon, there will be a demand for higher standards and more transparency and possibly laws regulating the production and testing of CBD products.
Diverse Phytocannabinoid-Rich and Terpenoid-Rich Blends Will Get More Attention
In addition to higher standards for lab testing, consumers are also now becoming more aware of the many other cannabinoids and the compounding effect that occurs from using multiple cannabinoids known as the Entourage Effect
This will lead to a higher demand for diverse cannabinoid-rich and terpenoid-rich CBD blends, which brands like Joy Organics, had predicted earlier and have already introduced a variety of cannabinoid-rich blends into their products.
Industrialization and Innovations Will Lead to New CBD Consumption Methods
In addition to diversified CBD blends, as the industry continues to develop, innovation and increased market competition will lead to the development of new ways to use CBD.
Through product diversification, brands will offer more value and features to their products. This will lead to the development of new vertical and horizontal markets that will continue to bolster the growth of the CBD industry.
Consumers Will Catch On to Unethical Business Practices
In the early stages of the CBD industry, and still, even now, there were a lot of unknown variables. Because of this, it was difficult, and even impossible, to set proper guidelines to regulate the industry as it continued to grow.
While many brands operated with integrity and maintained ethical business practices even when no one was looking, there were, and still are, many others who took advantage of the situation.
From inadequate lab testing and photo-shopped lab reports to inaccurate product labels and shady marketing tactics, unethical business behavior has been rampant due to the lack of regulatory guidelines and consumer awareness.
Now that consumers are more educated and continuing to learn more, unethical practices are beginning to be brought to light.
Increased Involvement from Major Brands and Retailers
Estimated to reach a market valuation of more than $25 billion by 2025, the CBD market is one of the biggest opportunities of the decade. Of course, this has gained the attention of major brands and big-box retailers like Walmart, Amazon, and Whole Foods.
While the products offered by these mega-brands seem modest, in 2020, these brands will use their full resources to unleash a massive presence in the CBD industry.
Are You Ready for 2020?
While 2019 was off to a slow start, it’s ending much quicker than it began. In a few days, it’ll be Christmas and before you know it, the new year will begin. Based on the trends we’ve seen, there’s a lot in store for 2020 and we’re ready to take it head-on.
Do you have any predictions or insights to add to the list or any comments to add? Share your insights in the comments below, we’d love to hear from you.
Thanks for joining us and making 2019 an amazing year!
The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology
Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects,…
Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects, including memory, pain, reproduction, bone remodeling or immunity, to name a few. Unsurprisingly, given these broad physiological effects, alterations of the ECS have been found in different diseases, including cancer. In recent years, the medical use of cannabis has been approved in different countries for a variety of human conditions. However, the use of these compounds, specifically as anticancer agents, remains controversial. Studies have shown that cannabinoids do have anticancer activity in different tumor types such as breast cancer, melanoma, lymphoma and adult brain cancer. Specifically, phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) has been shown to induce apoptosis and inhibit proliferation of adult cancer cells, as well as modulate angiogenesis and metastasis. Despite increasing evidence that cannabinoids elicit antitumor effects in adult cancers, there is minimal data available on their effects in children or in pediatric cancers despite public and clinical demand for information. Here we describe a comprehensive and critical review of what is known about the effects of cannabinoids on pediatric cancers, highlight current gaps in knowledge and identify the critical issues that need addressing before considering these promising but controversial drugs for use in pediatric oncology.
Keywords: CBD; THC; cannabidiol; cannabinoid; childhood cancer; medical cannabis; pediatric oncology; Δ9-tetrahydrocannabinol.
Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment
Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been…
Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results from the affinity of these compounds predominantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CB1), type two (CB2), and the G protein-coupled receptor 55 (GPR55)) but, also, for peroxisome proliferator-activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in Cannabis sp. raw material is also expressed in their increased bioavailability and penetration through the blood-brain barrier. This review provides an overview of phytochemistry and pharmacology of compounds present in Cannabis extracts in the context of the current knowledge about their synergistic actions and the implications of clinical use in the treatment of selected diseases.
Keywords: Cannabis; multitarget; phytocannabinoids (THC and CBD); receptors; terpenes.
Pervasive cropland in protected areas highlight trade-offs between conservation and food security
Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use…
Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use our global synthesis cropland dataset to quantify cropland in protected areas globally and assess their relationship to conservation aims and socio-environmental context. We estimate that cropland occupies 1.4 million km2 or 6% of global protected area. Cropland occurs across all protected area management types, with 22% occurring in strictly protected areas. Cropland inside protected areas is more prevalent in countries with higher population density, lower income inequality, and with higher agricultural suitability of protected lands. While this phenomenon is dominant in midnorthern latitudes, areas of cropland in protected areas of the tropics and subtropics may present greater trade-offs due to higher levels of both biodiversity and food insecurity. Although area-based targets are prominent in biodiversity goal-setting, our results show that they can mask persistent anthropogenic land uses detrimental to native ecosystem conservation. To ensure the long-term efficacy of protected areas, post-2020 goal setting must link aims for biodiversity and human health and improve monitoring of conservation outcomes in cropland-impacted protected areas.
Keywords: CBD; area-based targets; conservation; food security; protected areas.
Conflict of interest statement
The authors declare no competing interest.
- Klein Goldewijk K., Beusen A., Doelman J., Stehfest E.. New anthropogenic land use estimates for the holocene: HYDE 3.2. Earth Syst. Sci. Data. 2017;9:927–953.
- Barrett C. B.. Measuring food insecurity. Science. 2010;327:825–828.
- Fogel R. W.. The Escape from Hunger and Premature Death, 1700-2100: Europe, America, and the Third World. 2004.
- Crist E., Mora C., Engelman R.. The interaction of human population, food production, and biodiversity protection. Science. 2017;356:260–264.
- Pimm S. L., Vijay V.. Population, Agriculture, and Biodiversity: Problems and Prospects. 2020;365.
What are Some Major Factors to Keep in Mind When Buying CBD Vape Oil?
New York Small Business Cooperative License
New York Cannabis Distributor License
MagicMed: Bringing the Drug Candidate Library Model to Psychedelics
The USDA Has Released Its Final Rule on Hemp Regulation
New York Cannabis Delivery License
Investors in This Cannabis Stock Are Leaving $800 Million on the Table
What is Delta-8 THC? Everything You Need to Know
What’s New With Cannabis Stocks for the Week Ending 01/15/21
Cannabis Nursery in New York
New York’s Marijuana Cultivation License
Optical Coherence Tomography Findings in Cannabis Users
CBD News: Clint Eastwood files third suit against CBD companies, saying they’re falsely claiming endorsement
France’s “recreational” cannabis survey • New Mexico governor prioritizes legalization • California eases banking access • & more…
CBD News Roundup: FDA Provides Framework for Future CBD Research
New York’s Adult-Use Processor License
Airfield Supply Co. And Kiva Confections Launch Breast Cancer Awareness Campaign
Some Oddly Specific Predictions About Films You Should Keep an Eye Out For This Year
Antioxidant Function of Phytocannabinoids: Molecular Basis of Their Stability and Cytoprotective Properties under UV-irradiation
New York Cannabis Microbusiness License
New York Cannabis Dispensary License
Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis
CBD News: NIHC chairman appointed to board advising U.S. on trade policy
Alcanna to Spin Out Cannabis Business and Pursue Value Segment Strategy
Fire & Flower Expands Free Same-Day Delivery Across Its Ontario Network
Blog – Global Cannabinoids | CBD Wholesale & Bulk | White Label | Private Label
Hemp & CBD Blog | Northeast Kingdom Hemp
Informational blogs about CBD and Hemp
CBD Blog: News, Info & Tips
Clinical and biochemical heterogeneity of Parkinson’s disease
News1 week ago
Pure Harvest Bolsters Corporate Team with Key Additions
Heartland6 days ago
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
Heartland1 week ago
Compared to Prescription Medication, Medical Cannabis Not Always Affordable Alternative
Heartland1 week ago
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
Heartland1 week ago
Novamind Appoints Chuck Rifici to its Board of Directors
Uncategorized1 week ago
Sundial Announces the Launch of Premium Concentrates Products Under its Top Leaf Brand
Heartland1 week ago
Can You Treat COVID-19 With CBD and Reduce Mortality Rates? A New Israeli Research Believes You Can!
Uncategorized5 days ago
MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors